SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck & Co. is currently trending as speculation intensifies regarding its role in potential major oncology acquisitions, with community members actively debating its prospects as a suitor for companies like Sellas Life Sciences and Inhibrx. Investors are closely tracking these rumors against the backdrop of Merck's strategic need to bolster its pipeline to mitigate the impending impact of the patent cliff on its blockbuster franchise, Keytruda.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is facing intense volatility and community concern following the discovery of a critical vulnerability in its privacy protocol that theoretically allowed for unauthorized coin issuance. While the team has released a patch and disputes that any exploitation occurred, investors are deeply divided as the lack of transaction transparency creates uncertainty regarding the total circulating supply.

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is attracting significant attention as investors track the imminent release of phase 3 IZAR-1 trial results in psoriatic arthritis, with the community actively speculating on a potential buyout given the company's strong cash position and best-in-class immunology pipeline. Recent institutional interest through a large equity raise has set a new floor, while sentiment remains intensely focused on whether the upcoming data will trigger a major bidding war from big pharma.

C3.ai, Inc. engages in the provision of enterprise artificial intelligence software for digital transformation. It delivers the C3 AI suite for developing, deploying, and operating large-scale AI, predictive analytics, and Internet of Things applications in addition to a portfolio of turn-key AI applications. It operates through the following geographical segments: North America, Europe, The Middle East, and Africa, Asia Pacific, and Rest of World. The company was founded by Thomas M. Siebel, Patricia A. House and Stephen Maurice Ward, Jr. on January 8, 2009 and is headquartered in Redwood City, CA.

C3.ai Inc - Ordinary Shares - Class A

C3.ai Inc

C3.ai is currently trending as investors weigh aggressive institutional accumulation and high short interest against concerns regarding revenue growth and a complex sales turnaround. The community is heavily focused on the company's recent leadership shifts and the potential for a short squeeze, while debates persist over whether its enterprise software strategy can compete effectively in the broader AI sector.

Mastercard, Inc. is a technology company, which engages in the provision of payment solutions for the development and implementation of credit, debit, prepaid, commercial, and payment programs through its brands including Mastercard, Maestro, and Cirrus. It also offers cyber and intelligence solutions. The company was founded in November 1966 and is headquartered in Purchase, NY.

Mastercard Incorporated - Ordinary Shares - Class A

Mastercard Inc

Mastercard is drawing investor attention as it navigates a volatile market environment shaped by potential regulatory scrutiny over credit card interest rate caps and broader AI-driven fintech disruption. While community members remain divided on whether these pressures represent a long-term threat to the company's payment rail dominance, many are actively monitoring the stock as a potential value opportunity given its consistent cash flow and high-quality fundamentals compared to high-beta growth plays.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

Johnson & Johnson remains a focal point for institutional investors due to its defensive stability and strong pharma pipeline, with market participants closely monitoring potential M&A activity and the impact of ongoing talc-related litigation. The stock continues to be a core holding for those seeking reliable growth and consistent dividend returns amid broader market rotation into healthcare.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

Hedera Hashgraph is currently trending as the community debates its long-term potential amid a recent security incident involving a protocol hack and persistent price volatility. Investors remain divided between bullish long-term supporters focused on enterprise adoption and institutional utility, and bearish voices concerned about tokenomics, dilution, and the asset's underperformance relative to historical price levels.

ASML Holding NV engages in the development, production, marketing, sales, upgrading and servicing of advanced semiconductor equipment systems. It includes lithography, metrology and inspection systems. The company was founded on April 1, 1984 and is headquartered in Veldhoven, the Netherlands.

ASML Holding NV - New York Shares

ASML Holding NV

ASML remains at the center of investor focus as the essential lithography bottleneck for the global AI infrastructure buildout, with community sentiment shifting toward long-term structural demand despite near-term valuation volatility. While some market participants debate potential capacity constraints and export regulation risks, many traders view the stock's recent pullbacks as high-conviction accumulation opportunities given its indispensable role in manufacturing advanced chips for hyperscalers and foundry leaders.

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

Avalanche (AVAX) is experiencing significant downward pressure, fueling intense community debate over whether current price levels represent a deep-value buying opportunity or a structural decline. Investors are polarized, with some highlighting strong enterprise partnerships and RWA (Real World Asset) integration as signs of long-term potential, while others are frustrated by consistent underperformance and are comparing the token's trajectory to failed or manipulated projects.

SPX6900 is an advanced blockchain cryptography token coin capable of limitless possibilities and scientific utilization.

SPX6900

SPX6900 continues to trend as a community-driven "pure belief" asset, with followers frequently comparing its trajectory and cult-like devotion to the early days of Bitcoin or GameStop. The community remains hyper-focused on DCA strategies and social mobilization, positioning the token as a rebellious alternative to traditional equity markets while actively ignoring broader volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neutral Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

CRDSCrossroads Systems Inc.

Latest CRDS News